Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2008-3-24
pubmed:abstractText
Cytochrome P450 2E1 (CYP2E1) has been detected in brain regions which are of relevance for the pathophysiology of Parkinson's disease, such as the substantia nigra (SN). Furthermore, CYP2E1 is known to generate reactive oxygen species (ROS), toxic molecules which have been implicated in the pathogenesis of the disease. We have previously reported that CYP2E1 inhibition increases extracellular dopamine (DA) in the SN. The aims of the present study were by using in vivo microdialysis in rat, to elucidate the mechanisms responsible for the increase in extracellular DA induced by CYP2E1 inhibition and to explore whether ROS is produced in the SN, both with and without the presence of an exogenous CYP2E1 substrate. The effect of inhibition of CYP2E1 by phenylethyl isothiocyanate (100 mg/kg) on extracellular DA in the SN was unaltered following pretreatment with gamma-butyrolactone and GBR-12909, drugs that inhibit firing of DA neurons and DA re-uptake, respectively. Preadministration of tetrodotoxin or reserpine, however, abolished the effect of CYP2E1 inhibition. Administration of isoflurane, an anesthetic which is metabolized by CYP2E1, increased the production of *OH in the SN, as measured by the transformation of 4-hydroxybenzoic acid to 3,4-dihydroxybenzoic acid during local perfusion compared with animals given other anesthetics. The results support the notion that CYP2E1 is located near or in the same compartment in the SN as stored DA, tentatively the endoplasmatic reticulum, and that the enzyme activity might modulate the amount of DA that is available for release. Furthermore, our findings indicate that the production of ROS can be stimulated by CYP2E1 substrates.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/4-Butyrolactone, http://linkedlifedata.com/resource/pubmed/chemical/4-hydroxybenzoic acid, http://linkedlifedata.com/resource/pubmed/chemical/Adrenergic alpha-Agonists, http://linkedlifedata.com/resource/pubmed/chemical/Anesthetics, Dissociative, http://linkedlifedata.com/resource/pubmed/chemical/Anesthetics, Inhalation, http://linkedlifedata.com/resource/pubmed/chemical/Cytochrome P-450 CYP2E1, http://linkedlifedata.com/resource/pubmed/chemical/Dopamine Antagonists, http://linkedlifedata.com/resource/pubmed/chemical/Dopamine Uptake Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Free Radicals, http://linkedlifedata.com/resource/pubmed/chemical/GABA Modulators, http://linkedlifedata.com/resource/pubmed/chemical/Hydroxybenzoic Acids, http://linkedlifedata.com/resource/pubmed/chemical/Isoflurane, http://linkedlifedata.com/resource/pubmed/chemical/Ketamine, http://linkedlifedata.com/resource/pubmed/chemical/Parabens, http://linkedlifedata.com/resource/pubmed/chemical/Piperazines, http://linkedlifedata.com/resource/pubmed/chemical/Reserpine, http://linkedlifedata.com/resource/pubmed/chemical/Tetrodotoxin, http://linkedlifedata.com/resource/pubmed/chemical/Xylazine, http://linkedlifedata.com/resource/pubmed/chemical/protocatechuic acid, http://linkedlifedata.com/resource/pubmed/chemical/vanoxerine
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0887-4476
pubmed:author
pubmed:copyrightInfo
(c) 2008 Wiley-Liss, Inc.
pubmed:issnType
Print
pubmed:volume
62
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
379-88
pubmed:meshHeading
pubmed-meshheading:18288650-4-Butyrolactone, pubmed-meshheading:18288650-Adrenergic alpha-Agonists, pubmed-meshheading:18288650-Anesthetics, Dissociative, pubmed-meshheading:18288650-Anesthetics, Inhalation, pubmed-meshheading:18288650-Animals, pubmed-meshheading:18288650-Cytochrome P-450 CYP2E1, pubmed-meshheading:18288650-Dopamine, pubmed-meshheading:18288650-Dopamine Antagonists, pubmed-meshheading:18288650-Dopamine Uptake Inhibitors, pubmed-meshheading:18288650-Enzyme Inhibitors, pubmed-meshheading:18288650-Extracellular Space, pubmed-meshheading:18288650-Free Radicals, pubmed-meshheading:18288650-GABA Modulators, pubmed-meshheading:18288650-Hydroxybenzoic Acids, pubmed-meshheading:18288650-Isoflurane, pubmed-meshheading:18288650-Ketamine, pubmed-meshheading:18288650-Male, pubmed-meshheading:18288650-Microdialysis, pubmed-meshheading:18288650-Parabens, pubmed-meshheading:18288650-Piperazines, pubmed-meshheading:18288650-Rats, pubmed-meshheading:18288650-Rats, Sprague-Dawley, pubmed-meshheading:18288650-Reserpine, pubmed-meshheading:18288650-Substantia Nigra, pubmed-meshheading:18288650-Synaptic Transmission, pubmed-meshheading:18288650-Tetrodotoxin, pubmed-meshheading:18288650-Xylazine
pubmed:year
2008
pubmed:articleTitle
Cytochrome P450 2E1 in the substantia nigra: relevance for dopaminergic neurotransmission and free radical production.
pubmed:affiliation
Department of Pharmacology, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at Göteborg University, Göteborg, Sweden. haydeh.niazi@pharm.gu.se
pubmed:publicationType
Journal Article, In Vitro, Research Support, Non-U.S. Gov't